Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence

被引：0
|
作者：
Rosa Escudero-Sanchez
Antonio Ramos-Martínez
Antonio F. Caballero-Bermejo
Beatriz Díaz-Pollán
Guillermo Ruiz-Carrascoso
María Olmedo Samperio
Patricia Muñoz García
Paloma Merino Amador
Fernando González Romo
Oriol Martín Segarra
Gema Navarro Jiménez
Laura del Campo Albendea
Alfonso Muriel García
Javier Cobo
机构：
[1] Ramon y Cajal University Hospital,Infectious Disease Department
[2] Instituto de Salud Carlos III (IRYCIS),Center for Biomedical Research in Infectious Diseases Network (CIBERINFEC)
[3] Instituto de Salud Carlos III,Internal Medicine Department
[4] University Hospital Puerta de Hierro-Majadahonda,Pharmacology Department
[5] University Hospital Puerta de Hierro-Majadahonda,Infectious Diseases Unit, Internal Medicine Department
[6] La Paz University Hospital,Microbiology Department
[7] La Paz Institute for Health Research (IdiPAZ),Microbiology and Infectious Disease Department
[8] La Paz University Hospital,Microbiology Department
[9] Gregorio Marañón University Hospital,Infectious Disease Department
[10] Clínico San Carlos University Hospital,Biostatistics Unit
[11] Fundación Alcorcon University Hospital,undefined
[12] University Hospital Ramon y Cajal,undefined
[13] Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP),undefined
[14] Universidad de Alcalá,undefined
来源：
European Journal of Clinical Microbiology & Infectious Diseases | 2024年 / 43卷
关键词：
Bezlotoxumab; infection; Recurrence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：533 / 540
页数：7
相关论文
共 50 条
  • [21] Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
    Mileto, Steven J.
    Hutton, Melanie L.
    Walton, Sarah L.
    Das, Antariksh
    Ioannidis, Lisa J.
    Ketagoda, Don
    Quinn, Kylie M.
    Denton, Kate M.
    Hansen, Diana S.
    Lyras, Dena
    GUT MICROBES, 2022, 14 (01)
  • [22] Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection
    Chen, Jiahe
    Gong, Cynthia L.
    Hitchcock, Matthew M.
    Holubar, Marisa
    Deresinski, Stanley
    Hay, Joel W.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) : 1448 - 1454
  • [23] Bezlotoxumab for Prevention of Recurrent C. difficile Infection in High-Risk Patients
    Sangha, Maheep Singh
    Kelly, Colleen R.
    PRACTICAL GASTROENTEROLOGY, 2020, 44 (10) : 20 - 25
  • [24] Risk factors for the development of Clostridioides difficile infection in patients colonized with toxigenic Clostridioides difficile
    Clement, Josh
    Barlingay, Gauri
    Addepalli, Sindhu
    Bang, Heejung
    Donnelley, Monica A.
    Cohen, Stuart H.
    Crabtree, Scott
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2025,
  • [25] Recurrent Clostridioides difficile Infection in Patients Treated With Bezlotoxumab: Systematic Review and Meta-Analysis
    Mohamed, Mouhand F.
    Ward, Christopher
    Beran, Azizullah
    Abdallah, Mohamed
    Kelly, Colleen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S110 - S111
  • [26] Recurrence of Clostridioides difficile infection: A multicenter study on incidence and risk factors
    Cataldo, M. A.
    Granata, G.
    Caraffa, E.
    Adamoli, L.
    Borromeo, R.
    Fossati, S.
    Franceschini, E.
    Giacobbe, D. R.
    Giacometti, E.
    Lagi, F.
    Lombardi, A.
    Oliva, A.
    Pandolfo, A.
    Trapani, F.
    Petrosillo, N.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 101 : 273 - 274
  • [27] Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides Difficile Infection among Transplant Recipients
    Bajrovic, V.
    Johnson, T.
    Howard, A.
    Allen, L.
    Barber, G.
    Schwarz, K.
    Huang, M.
    Abidi, M.
    Benamu, E.
    Ramanan, P.
    Miller, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 374 - 374
  • [28] How Should We Determine the Role of Bezlotoxumab for Pediatric Clostridioides difficile Infection?
    Sandora, Thomas J.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2023, 12 (06) : 332 - 333
  • [29] Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
    Johnson, Tanner M.
    Howard, Amanda H.
    Miller, Matthew A.
    Allen, Lorna L.
    Huang, Misha
    Molina, Kyle C.
    Bajrovic, Valida
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (07):
  • [30] ARE CIRRHOTIC PATIENTS AT INCREASED RISK FOR CLOSTRIDIOIDES DIFFICILE INFECTION?
    Asfari, Mohammad Maysara
    Sarmini, Muhammad Talal
    Uy, Pearl Princess
    Alkaddour, Ahmad
    Perry, Isaac E.
    Yap, John Erikson
    GASTROENTEROLOGY, 2020, 158 (06) : S1473 - S1473
12345